If Stanton's pps target is post-EPP aproval, then he's talking about a 56% return on investment henceforward.
For most investments, a 56% return is outstanding. But, when you're talking about the risks of regulatory approval decisions (risky for ANY pharma / biotech stock), a 56% return on a first in-class drug is not as great of a risk/ reward profile to me as it would appear at first glance.
For other biotechs that I have seen, there is much bigger upside potential for post-approval.
Having said that, I feel this drug will be approved (I've always said that) and that there is less risk than most other first in-class drug applications out there.
Also, Stanton's call is not gospel.
But there are biotechs out there that perform better than 56% 6-9 months outside of approval.
Remember, we're competiting with other pharma / biotech investments given investors in this space are looking for the best investment opportunities out there for their money.
- Forums
- ASX - By Stock
- CUV
- 56 percent return on cuv?
56 percent return on cuv?
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.09 |
Change
0.100(0.71%) |
Mkt cap ! $705.3M |
Open | High | Low | Value | Volume |
$14.00 | $14.30 | $13.93 | $676.4K | 47.95K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200 | $14.04 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.16 | 405 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 14.040 |
1 | 150 | 13.920 |
2 | 6000 | 13.900 |
1 | 527 | 13.890 |
2 | 728 | 13.850 |
Price($) | Vol. | No. |
---|---|---|
14.290 | 709 | 1 |
14.300 | 833 | 1 |
14.430 | 668 | 1 |
14.460 | 709 | 1 |
14.490 | 180 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |